1. EUDA launched a stem cell platform in China, enhancing healthcare access. 2. Partnerships include Shenzhen Inno Immune and Wuhan Kaien Hospital. 3. The platform integrates cryogenic storage and clinical delivery nationally. 4. Designed for compliance, the system supports 200,000 patient units. 5. Focus on longevity medicine highlights the shift to proactive healthcare.
FAQ
Why Bullish?
The expansion into China's healthcare market addresses key growth areas in longevity, similar to companies like CRISPR Therapeutics which saw boosts from similar innovations.
How important is it?
The strategic partnerships and platform enhance EUDA's competitive position in a growing market, aligning with regional healthcare trends.
Why Long Term?
The infrastructure build and strategic partnerships will take time to realize returns, much like established healthcare networks in the region.
EUDA Launches Nationwide Stem Cell Platform in China
SINGAPORE, Dec. 30, 2025 (GLOBE NEWSWIRE) – EUDA Health Holdings Limited (NASDAQ: EUDA), a non-invasive healthcare provider based in Singapore, has announced the launch of its nationwide stem cell extraction, cryogenic storage, and clinical delivery platform in China. This initiative, developed in collaboration with Shenzhen Inno Immune Co., Ltd. and Wuhan Kaien Hospital, is a critical milestone in EUDA’s strategy to enhance its healthcare offerings across both extraction and clinical logistics.
Core Design Principles of EUDA’s Platform
The newly established platform is built upon three key principles:
- Centralized Processing: Ensuring quality and compliance while extending geographical access.
- Long-Term Preservation: Allowing patients to store biological material early in life for future clinical usage.
- Integration with Longevity Medicine: Embedding cell services within comprehensive preventive and regenerative health programs.
National Stem Cell Extraction and Cryostorage Infrastructure
EUDA’s platform features a closed-loop operational system designed to provide extensive access to stem cell services while ensuring high processing standards.
Key components of this infrastructure include:
- Shenzhen Inno Immune Co., Ltd.: The primary processing and cryogenic storage hub in Southern China, designed to hold approximately 50,000 patient cell units.
- Wuhan Kaien Hospital: Serving as the flagship in Central China, this facility aims to support up to 200,000 patient cell units and provides integrated health management services.
- Nationwide Clinical Access: Collaboration with partner clinics for local extraction and clinical delivery.
Wuhan Kaien Hospital: A Central Node in Regenerative Medicine
The Wuhan Kaien Hospital is positioned as a five-star health management center, focusing on longevity and preventive healthcare. It integrates various modern medical practices, including:
- Regenerative medicine.
- Hormonal and metabolic balance.
- Chronic disease management.
- Personalized health planning.
Within EUDA’s infrastructure, it acts as both a clinical service site and a central hub for stem cell processing and translation in the region.
Distributed Clinical Access in a Centralized Network
To achieve nationwide access, EUDA has partnered with two significant players:
- Guangdong Wanhai Cell Biotechnology Co., Ltd.: Operates a network of GMP-standardized laboratories and clinical clinics across over 20 provinces, facilitating extraction and clinical preparation.
- Shunfeng Cold Chain Logistics Co., Ltd.: Ensures secure transport of biological materials under controlled conditions, maintaining the integrity of patient samples.
This integrated network allows for seamless extraction of stem cells at local clinics, with subsequent transport and processing handled through strict cold-chain protocols. EUDA’s system facilitates efficient delivery of cell products back to treatment clinics, ensuring high-quality standards throughout.
CEO Remarks on the Transformative Platform
Mr. Alfred Lim, CEO of EUDA, stated, “This platform transforms how regenerative medicine is accessed and delivered in China. Instead of isolated clinics or laboratories, we are building a coordinated national system that connects extraction, cryogenic storage, logistics, and clinical delivery into one integrated ecosystem.”
Mr. Lim emphasized that with Shenzhen Inno Immune and Wuhan Kaien Hospital as anchors, along with a national network of clinic and logistics partners, EUDA is establishing a scalable infrastructure that facilitates access to innovative regenerative medical solutions.
About EUDA Health Holdings Limited
EUDA Health Holdings Limited (NASDAQ: EUDA) is a leading non-invasive healthcare provider in Asia, concentrating its efforts on Singapore, Malaysia, and China. The company is committed to addressing the evolving healthcare needs of over 1.8 billion people in the region, particularly as demographic shifts lead to a rapidly aging population. By providing cutting-edge, science-driven health solutions, EUDA aims to redefine regional healthcare from a reactive to a proactive, longevity-focused approach.
Forward-Looking Statements
This document may include forward-looking statements regarding risks and uncertainties. Such statements are identifiable by terms like "estimates," "projects," and "anticipates." These do not guarantee future performance and involve a range of known and unknown risks. Readers are advised not to rely on these statements beyond the publication date without considering potential positive and negative factors that may affect actual results.
Contact Information
For further inquiries, please contact:
Linda Bergkamp
Christensen Advisory
Phone: +1-480-614-3004
E-mail: linda.bergkamp@christensencomms.com